Shkreli basically lied about everything. He lied about his business model. He lied about the availability of the drugs. He lied about his programs that supposedly made the drug available to people who could not otherwise afford it. The guy is a real piece of work.
Watch the hearing on C-SPAN if you don't believe me.
http://www.c-span.org/video/?404183-1/hearing-prescription-d... http://www.c-span.org/video/?406885-1/sudden-price-spikes-de...
Found the timestamp, starts at 00:41:00 (second hearing) where victims of Martin Shkreli talks about their attempts to mortgage their house in order to pay for the drug for their sick child.
Are there proofs of the availability program but working outside this video? Seems like news people should document such cases and bring them up. Even better if they'd do so live on his webcam.
The reality is that all the executives at Turing were his hedge fund buddies, the investors were other hedge fund buddies and Shkreli made nearly a billion dollars in 3 years with his price-hiking shenanigans. In investor presentations he doesn't even refer to Turing as a pharma business nor does he talk about his planned pharmaceutical research, he presented the business as a pharma-hedgefund-hybrid: an easy way to make boatloads of money.
This isn't what you'd expect to see from somebody who is passionate about drug research and curing kids, this is what you expect to see from somebody who cynically exploits a system. That internal correspondence (again, subpoenaed) shows they're like "lol, sucker" whenever an individual pays the list price for their drugs makes it crystal clear how concerned they are about providing a service to humanity.
See e.g. http://democrats.oversight.house.gov/sites/democrats.oversig... for some nice quotes
I would say so, yes. Note how none of the products that they're supposedly developing are in clinical trials, despite being Turing Pharmaceuticals indicating they should be...
http://www.forbes.com/sites/johnlamattina/2015/12/15/martin-...
Searching for the word "mortgage" yielded no results for me.
I used to think drug companies were a scourge. After researching the Shkreli controversy last year I'm not so sure. But Shkreli, with his (often funny) dickhead antics, certainly would be a convenient whipping boy -- if anyone, like Congress or special interests -- needed a whipping boy to distract the public from what's actually ailing American health care.
For some perspective, drugs are only 1/10 of American health care costs.
Prescription drugs: 10%
Dental care: 4%
Hospital care: 32%
Physician/clinical services: 20%
Source: https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/Downloads/PieChartSourcesExpenditures2014.pdf
And as far as Shkreli goes, the reality, as far as I've seen so far, is that no one is paying these sky-high prices for Daraprim out of pocket. Check out Turing's 10-K's; they reinvest their profits in R+D. Shkreli himself seems to be legitimately interested in developing new and better treatments for rare diseases. (CMD+F: "PKAN" on this page: http://www.bloomberg.com/news/articles/2014-04-17/retrophins...)Serious question. For these super-rare diseases like toxoplasmosis, the current profit model is this. First, charge a high price ($30k-$100k) for a course of treatment. Then, the few people suffering from the rare disease get the drug via insurance. Does anyone have a better way of incentivizing drug companies to create new treatments, or better treatments, for rare diseases?
Also see page 4 of this document (which I already linked to):
http://democrats.oversight.house.gov/sites/democrats.oversig...
And in the congressional hearing there was one family facing a $350,000 price tag for their Daraprim cure which insurance refused to cover altogether because of the price hike, and Turing refused to help. The family did eventually get the medicine they needed, but Turing left them out to dry.
I'm fully aware Turing states "nobody falls through the cracks", but it's a blatant and audacious lie and there are dozens of experts testifying as much. You'll also find expert testimony in the linked videos. Many hospitals stock one or two bottles of Daraprim so they can immediately help walk-in patients. So now when somebody can't get Daraprim through insurance the doctors beg nearby hospitals to fedex the pills they have in stock from before the price hike. This supply is quickly running out.
The sales volume of Daraprim dropped by 80% or so as a result of the price increase, and the Turing executives state that thanks to their actions availability of the drug has broadened. A clear contradiction. Less volume means sick folks simple have to go without, which can have very serious health consequences.
Heck, even the Massachusetts General Hospital stated, and I quote!
This is a critical matter, visible at the highest levels of our
Infectious Disease Department [...] Daraprim’s new price on their
inpatient pharmacy budget, which they have determined to be
prohibitively expensive. Against their clinical convictions
they are currently switching patients to Bactrim.
Observe that patients who are now forced to use the inferior Bactrim do not deal with Turing at all, which means there is no application for Turing to reject. Translated into Turing's bizarro PR language: "nobody falls through the cracks". In the real world we understand that people not getting the medicine they need is a problem.Watch the hearing videos (especially the Subcommitte on Aging one). Read the actual filings and other primary sources, not the PR spin.
You're right about number 1.
You cite no evidence for number 2. For its part, Turing says they reimburse for the high co-pays. Why wouldn't they? It would be a PR disaster not to reimburse, so it's manifestly in their interest. And they're making such a fat profit they can afford to reimburse people for high co-pays.
Page 4 of the document you cited is just a list of examples of high co-pays. Yes.
Again, where's the evidence that Turing does NOT reimburse for those co-pays? Do you have an example?
From the memo I linked earlier:
> The email stated that the first patient “has a $6000.00 co-pay. She is not a Medicare part D but has a federal funded insurance plan so wouldn’t quali[f]y for co-pay assistance or be covered under whatever Medicare Part D plan you are working on right now with Turing.” The email stated that the second patient “has insurance, however her plan does not cover Daraprim. Attempted to transfer to UCB for free drug program but was advised that because she has insurance, she does not qualify. Free drug program is only for patients with no insurance.”
Basically, Turing says "sorry, you don't qualify". Turing denies people's claims repeatedly, because they just don't give a fuck. Not to mention the obvious problem of patients not being able to afford the co-pay, thereby having to go without the pills. I've clearly demonstrated that there are cases where patients cannot get the medicine they need as a direct consequence of the price hike. But hey, feel free to believe Turing is acting honorably because they want to protect their reputation. Believe whatever you want. I'm done here.
For example, that case you cite above, the $6k copay. OK. Read the memo closely. A Walgreens exec is emailing a Turing exec citing a patient's problem with Turing's bureaucracy.
How was the problem resolved? Did Turing pay? You say that CLEARLY Turing didn't end up paying in this particular case, because you hate Turing, but the document doesn't say. And you have no idea. Neither do I, but I'm not pretending.
Generally: Turing says, for goodwill, they give away 60% of the drug for a dollar.
Do you know of even one case where someone - verifiably - fell through the cracks and Turing refused to EVER pay?
Are you opposed to the idea of pharmaceutical companies selling orphan drugs at high prices ($100k, $300k, or more)? Or are you only opposed to Turing's purchase of Daraprim and raising the price? Would you still oppose them if, in 10 years, it turned out Turing's profits had, e.g., produced a PKAN drug? Do you know a better way than high drug prices to incentivize the creation of drugs for serious rare diseases?
Is it the sleazebag who legally takes advantage of the terrible system that we refer to as the US health insurance system?
Or is it the 435 representatives and 100 senators who are in the pockets of the insurance companies and pharma companies that perpetuate our current system?
At a moral level, yes the guy is as bad as they come (and those youtube videos of him are just plain weird). But I'd argue he's not the cause of our problems, he's a product of the system that we've cornered ourselves into.
So I agree he's not the root cause. He just pushes the existing framework to its "logical" conclusion. But only if "Logical" means being as ruthlessly exploitative as possible. Even the other sleazebag drug CEOs don't go this far, so Shkreli is uniquely contemptible.
But yes, ideally anger should be directed to the pharma industry and health insurance as a whole, not to Shkreli the individual.
The "either-or" is figuring out which one to go after and where to change things. If you only go after the Shkrelis, it's all for show and probably is a waste of tax payer money as he'll get off the hook for not legally doing anything wrong. People need to wake up and go after the real problem and replace the healthcare system and corrupt officials that perpetuate it.
Take a look then...
http://www.marketwatch.com/story/these-are-the-charges-again...
> http://www.marketwatch.com/story/these-are-the-charges-again....
Did you actually read that article?
It has nothing to do with price gouging prescription drugs. That's for an unrelated securities fraud charge for juggling hedge fund money. I'm not saying he's not at fault in that situation (honestly not sure) but it's unrelated.
http://www.legalreader.com/distribution-network-for-daraprim...
That was an adjustment made after the initial outrage over the price hikes.
Also, worth considering the "50% price cut" made for hospitals was after raising the original price by 5000%:
http://www.streetinsider.com/dr/news.php?id=11105404
Lastly, raising the costs for insurance companies raises insurance premiums for customers, if you think they'd let these price rises eat into their own profits I'd suggest that was a little misguided.
"Daraprim is used to treat a parasitic infection known as toxoplasmosis, which the Centers for Disease Control and Prevention considers a leading cause of death attributed to food-borne illnesses. The Toxoplasma parasite can be transmitted through contaminated food, water, and kitchen utensils as well as contact with infected cat feces. While 60 million Americans carry the parasite with no symptoms, it can become deadly for those with weakened immune systems."
""Turing has not got a single clinical trial underway. Shkreli’s not testing new drugs of any kind for toxoplasmosis. He's got nothing registered," Attaran said. "No one needs a new drug for toxoplasmosis anyways. It works so well bloody well.""
It's easy enough to make, but the FDA changes to older drugs' approval creates perfect conditions for such abuse. Zero other companies have stepped up and got approval yet.
Doesn't it take a while to get to clinical trials?
On a side note, regarding those 2000, there's evidence that toxoplasmosis is under treated in the US, particularly with regards to pregnant women.
https://med.stanford.edu/news/all-news/2011/10/u-s-not-takin...